Document is current
Any future updates will be listed below
-
Authors
Shah, Eric D.
Sharma, Amol
Curren, Nijmeh
Laitman, Adam P.
Staller, Kyle
-
Funding
Funding for this research was provided by:
Salix Pharmaceuticals (Technical editorial support)
Salix Pharmaceuticals (Open access/rapid fee funding)
Salix Pharmaceuticals (Employee salary)
- License Information
-
More Information
Article History
Received: 21 November 2025
Accepted: 13 May 2026
First Online: 12 June 2026
Change Date: 25 July 2026
Change Type: Update
Change Details: The original article was revised due to update in Table 1.
Declarations
Conflicts of Interest: Eric D. Shah reports being a consultant for AbbVie, Ardelyx, Cook Group, Laborie Medical Technologies, Mahana Therapeutics, Mylan (Viatris), NeurAxis, Salix Pharmaceuticals, Sanofi, and Takeda Pharmaceutical; holding stock in NeurAxis; and having a patent with the Regent of the University of Michigan. Amol Sharma is a consultant for Atmo Biosciences and has received research support from Vibrant Gastro. Nijmeh Curren and Adam P. Laitman are employees of Salix Pharmaceuticals. Kyle Staller has served as a consultant to Anji Pharmaceuticals, Ardelyx, Gemelli Biotech, Laborie Medical Technologies, Mahana Therapeutics, ReStalsis Health, Salix Pharmaceuticals, and Takeda Pharmaceutical, and has received research support from Ardelyx and ReStalsis Health.
Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
